

Dr Jörg Holger MOCH  
 Professor of Pathology, University Zurich, Switzerland  
 Chairman, Department of Pathology and Molecular Pathology,  
 University Hospital Zurich, Switzerland  
 Department of Pathology and Molecular Pathology  
 University Hospital Zurich  
 Schmelzbergstr. 12  
 CH-8091 Zurich  
 Switzerland  
 Tel.: +41-1-255 39 30  
 Fax: +41-1-255 44 16  
 Email: holger.moch@usz.ch



#### *Academic degrees*

Doctor of Medicine (MD) - Humboldt-University of Berlin, Germany (1988)  
 Habilitation (University Lecturer) – University Basel, Switzerland (1998)  
 Full Professor of Pathology, University Zurich, Switzerland Chairman, Department of  
 Pathology and Molecular Pathology, University Hospital Zurich, Switzerland (2004)

#### *Prizes and honors*

Member of the German Academy of Sciences “Leopoldina” (2007)  
 Member of the Swiss Academy of Medical Sciences (2015)

#### *Selected publications*

Nowicka AM, Hauselmann I, Borsig L, Bolduan S, Schindler M, Schraml P, Heikenwalder M, Moch H. A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization. *Oncogene* 2016; 35(24):3125-38.  
 Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. *International Journal of Cancer* 2016; 139(2):396-403.  
 Frew IJ, Moch H. A clearer view of the molecular complexity of clear cell renal cell carcinoma. *Annu Rev Pathol* 2015; 10:263-89.  
 Ruf M, Mittmann C, Nowicka AM, Hartmann A, Hermanns T, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma. *Clinical Cancer Research : an official journal of the American Association for Cancer Research* 2015; 21(4):889-98.  
 Deml KF, Schildhaus HU, Comperat E, von Teichman A, Storz M, Schraml P, Bonventre JV, Fend F, Fleige B, Nerlich A, Gabbert HE, GaBler N, Grobholz R, Hailemariam S, Hinze R, Knuchel R, Lhermitte B, Nesi G, Rudiger T, Sauter G, Moch H. Clear Cell

- Papillary Renal Cell Carcinoma and Renal Angiomyoadenomatous Tumor: Two Variants of a Morphologic, Immunohistochemical, and Genetic Distinct Entity of Renal Cell Carcinoma. *The American journal of Surgical Pathology* 2015; 39(7):889-901.
- Wylter L, Napoli CU, Ingold B, Sulser T, Heikenwalder M, Schraml P, Moch H. Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. *British Journal of Cancer* 2014; 110(3):686-94.
- Pflueger D, Sboner A, Storz M, Roth J, Comperat E, Bruder E, Rubin MA, Schraml P, Moch H. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. *Neoplasia* 2013; 15(11):1231-40.
- Casagrande S, Ruf M, Rechsteiner M, Morra L, Brun-Schmid S, von Teichman A, Krek W, Schraml P, Moch H. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma. *The Journal of Pathology* 2013; 229(4):525-34.
- Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, Beerenwinkel N. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. *Nat Commun* 2012; 3:811.